TL;DR

Pfizer (NYSE: PFE) filed an 8-K on June 18, 2026 disclosing that Chief Financial Officer Dave Denton is stepping down effective August 15, 2026, to take a job in consumer goods. Senior finance executive Cecile Guegan becomes Interim CFO on August 16 while Pfizer searches for a permanent replacement.

What was filed

The filing (Item 5.02) lays out a leadership change in Pfizer's finance organisation:

• Denton notified Pfizer on June 16 that he will leave to pursue an opportunity outside the pharmaceutical industry, in consumer goods.
• Pfizer states his departure is not related to any disagreement over the company's financial, operational, accounting or reporting practices, and not tied to its results.
• Cecile Guegan, 55, currently SVP, Finance for the Global Biopharmaceutical Business, will serve as Interim CFO from August 16. She joined Pfizer in 2005 and has held senior finance roles across R&D and multiple regions.
• Pfizer is running a comprehensive search, internal and external, for a permanent CFO.

What an 8-K is

An 8-K is a "current report" US companies must file with the SEC to flag major events between their quarterly and annual reports, so investors learn material news at the same time. Item 5.02 specifically covers the departure or appointment of directors and key officers, the CFO being one of the most closely watched. It is a disclosure document, not an earnings report; it tells you what happened, not how the stock should move.

Why it matters

The CFO is the person investors trust to steward the numbers, manage the balance sheet and communicate guidance. A CFO change at a company Pfizer's size naturally draws attention because:

• Continuity: markets like stability in the finance seat, especially while Pfizer manages patent cliffs, cost cuts and its pipeline. Naming an experienced 20-year insider as interim signals continuity rather than disruption.
• Tone of the exit: the filing's explicit note that there were no disagreements over accounting or results is standard language meant to reassure that this is a personal career move, not a red flag.
• Open questions: an interim tag and an open external search mean the permanent pick, and any change in financial strategy, is still to come.

None of this predicts where the share price goes; it simply changes who holds a key seat.

Beginner takeaway

A CFO leaving sounds dramatic, but context matters. Here it is a planned, amicable exit with an experienced insider stepping in immediately, which is about as orderly as these transitions get. The thing to watch is who Pfizer ultimately hires and whether the strategy shifts with them.

FAQ

Is a CFO leaving a bad sign? Not necessarily. It only becomes a concern if the exit is sudden, unexplained, or linked to accounting disputes. This filing explicitly says none of those apply.

What does "Interim CFO" mean? It is a temporary appointment to keep the finance function running smoothly while the board searches for a permanent CFO. The interim leader has full responsibilities in the meantime.

Why does the filing mention there were no disagreements? SEC rules effectively require companies to disclose if an officer left over a dispute. Stating there were none is the company confirming this is a routine, voluntary departure.

Where can I read the original? The 8-K and the attached press release are public on the SEC's EDGAR database, linked below.

As of June 18, 2026. Source: official SEC filing — read it directly here. We summarise filings for education and may make errors, so always verify against the official document. Educational content only — not investment advice, not a buy/sell recommendation.